These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 18621077

  • 1. Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk.
    Gintant GA.
    Pharmacol Ther; 2008 Aug; 119(2):199-209. PubMed ID: 18621077
    [Abstract] [Full Text] [Related]

  • 2. The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?
    Lee N, Authier S, Pugsley MK, Curtis MJ.
    Toxicol Appl Pharmacol; 2010 Mar 01; 243(2):146-53. PubMed ID: 20005885
    [Abstract] [Full Text] [Related]

  • 3. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety.
    Gintant GA, Su Z, Martin RL, Cox BF.
    Toxicol Pathol; 2006 Mar 01; 34(1):81-90. PubMed ID: 16507548
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The canine model with chronic, complete atrio-ventricular block.
    Oros A, Beekman JD, Vos MA.
    Pharmacol Ther; 2008 Aug 01; 119(2):168-78. PubMed ID: 18514320
    [Abstract] [Full Text] [Related]

  • 6. Early clinical development: evaluation of drug-induced torsades de pointes risk.
    Vik T, Pollard C, Sager P.
    Pharmacol Ther; 2008 Aug 01; 119(2):210-4. PubMed ID: 18601950
    [Abstract] [Full Text] [Related]

  • 7. Torsades de pointes liability inter-model comparisons: the experience of the QT PRODACT initiative.
    Hashimoto K.
    Pharmacol Ther; 2008 Aug 01; 119(2):195-8. PubMed ID: 18486227
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL, Pollard CE, Hammond TG, Valentin JP.
    J Pharmacol Toxicol Methods; 2005 Aug 01; 52(1):46-59. PubMed ID: 15975832
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias.
    Thomsen MB, Matz J, Volders PG, Vos MA.
    Pharmacol Ther; 2006 Oct 01; 112(1):150-70. PubMed ID: 16714061
    [Abstract] [Full Text] [Related]

  • 13. Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
    Said TH, Wilson LD, Jeyaraj D, Fossa AA, Rosenbaum DS.
    J Cardiovasc Pharmacol; 2012 Aug 01; 60(2):165-71. PubMed ID: 22561361
    [Abstract] [Full Text] [Related]

  • 14. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
    Lu HR, Vlaminckx E, Van de Water A, Rohrbacher J, Hermans A, Gallacher DJ.
    Eur J Pharmacol; 2006 Dec 28; 553(1-3):229-39. PubMed ID: 17054943
    [Abstract] [Full Text] [Related]

  • 15. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.
    Hoffmann P, Warner B.
    J Pharmacol Toxicol Methods; 2006 Dec 28; 53(2):87-105. PubMed ID: 16289936
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation.
    Gintant G.
    Pharmacol Ther; 2011 Feb 28; 129(2):109-19. PubMed ID: 20807552
    [Abstract] [Full Text] [Related]

  • 19. Ventricular rate adaptation: a novel, rapid, cellular-based in-vitro assay to identify proarrhythmic and torsadogenic compounds.
    Green JR, Diaz GJ, Limberis JT, Houseman KA, Su Z, Martin RL, Cox BF, Kantor S, Gintant GA.
    J Pharmacol Toxicol Methods; 2011 Feb 28; 64(1):68-73. PubMed ID: 21440075
    [Abstract] [Full Text] [Related]

  • 20. Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts.
    Sugiyama A.
    Br J Pharmacol; 2008 Aug 28; 154(7):1528-37. PubMed ID: 18552873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.